Artículos por temáticas

Cognitive impairment in carriers of glucocerebrosidase gene mutation in Parkinson disease patients.

Malec-Litwinowicz M, Rudzińska M, Szubiga M, Michalski M, Tomaszewski T, Szczudlik A.

Neurol Neurochir Pol. 2014;48(4):258-61. doi: 10.1016/j.pjnns.2014.07.005.

Influence of depressive symptoms on dopaminergic treatment of Parkinson's disease.

Hanganu A, Degroot C, Monchi O, Bedetti C, Mejia-Constain B, Lafontaine AL, Chouinard S, Bruneau MA.

Front Neurol. 2014 Sep 25;5:188. doi: 10.3389/fneur.2014.00188.

Knowledge and attitudes towards genetic testing in those affected with Parkinson's disease.

Scuffham TM, McInerny-Leo A, Ng SK, Mellick G.

J Community Genet. 2014 Apr;5(2):167-77. doi: 10.1007/s12687-013-0168-7.

Initial medication in patients of newly diagnosed Parkinson's disease in Taiwan.

Guo YJ, Liao YC, Lin CH, Chang MH.

PLoS One. 2014 Sep 15;9(9):e107465. doi: 10.1371/journal.pone.0107465.

MitoPark mice, an animal model of Parkinson's disease, show enhanced prepulse inhibition of acoustic startle and no loss of gating in response to the adenosine A(2A) antagonist SCH 412348.

Grauer SM, Hodgson R, Hyde LA.

Psychopharmacology (Berl). 2014 Apr;231(7):1325-37. doi: 10.1007/s00213-013-3320-5.

Management of spasticity with severe painful myoclonic jerks in an operated case of spinal astrocytoma.

Jain P, Chava MK.

Indian J Anaesth. 2014 Nov-Dec;58(6):765-6. doi: 10.4103/0019-5049.147180. No abstract available.

Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.

Stafa K, Tsika E, Moser R, Musso A, Glauser L, Jones A, Biskup S, Xiong Y, Bandopadhyay R, Dawson VL, Dawson TM, Moore DJ.

Hum Mol Genet. 2014 Apr 15;23(8):2055-77. doi: 10.1093/hmg/ddt600.

Working memory deficit in patients with restless legs syndrome: an event-related potential study.

Kim SM, Choi JW, Lee C, Lee BU, Koo YS, Kim KH, Jung KY.

Sleep Med. 2014 Jul;15(7):808-15. doi: 10.1016/j.sleep.2014.03.010.

Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol.

Tournier BB, Ginovart N.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1415-23. doi: 10.1016/j.euroneuro.2014.04.003.

Biofeedback treatment for Tourette syndrome: a preliminary randomized controlled trial.

Nagai Y, Cavanna AE, Critchley HD, Stern JJ, Robertson MM, Joyce EM.

Cogn Behav Neurol. 2014 Mar;27(1):17-24. doi: 10.1097/WNN.0000000000000019.

Glass fairies and "bone children": adolescents and young adults with anorexia nervosa show positive reactions towards extremely emaciated body pictures measured by the startle reflex paradigm."

Reichel VA, Schneider N, Grünewald B, Kienast T, Pfeiffer E, Lehmkuhl U, Korte A.

Psychophysiology. 2014 Feb;51(2):168-77. doi: 10.1111/psyp.12160.

Novel DYT11 gene mutation in patients without dopaminergic deficit (SWEDD) screened for dystonia.

Cilia R, Reale C, Castagna A, Nasca A, Muzi-Falconi M, Barzaghi C, Marzegan A, Granata M, Marotta G, Sacilotto G, Vallauri D, Pezzoli G, Goldwurm S, Garavaglia B.

Neurology. 2014 Sep 23;83(13):1155-62. doi: 10.1212/WNL.0000000000000821.

Diabetes and risk of Parkinson's disease: an updated meta-analysis of case-control studies.

Lu L, Fu DL, Li HQ, Liu AJ, Li JH, Zheng GQ.

PLoS One. 2014 Jan 21;9(1):e85781. doi: 10.1371/journal.pone.0085781.

Neurometabolic disorder with microcephaly, dystonia, and central cyanosis masquerading as cerebral palsy.

Devadathan K, Sreedharan M, Sarasam S, Colah RB, Kunju PA.

J Child Neurol. 2014 Nov;29(11):NP139-42. doi: 10.1177/0883073813512026.

Therapy for Parkinson's disease: what is in the pipeline?

Stocchi F.

Neurotherapeutics. 2014 Jan;11(1):24-33. doi: 10.1007/s13311-013-0242-1. Review.